

Clinical Policy: Avelumab (Bavencio)

Reference Number: CP.PHAR.333

Effective Date: 05.01.17

Last Review Date: 02.22

Line of Business: Commercial, HIM, Medicaid

[Coding Implications](#)

[Revision Log](#)

See [Important Reminder](#) at the end of this policy for important regulatory and legal information.

Description

Avelumab (Bavencio[®]) is a programmed death ligand-1 blocking antibody.

FDA Approved Indication(s)

Bavencio is indicated for:

- Adults and pediatric patients 12 years and older with metastatic Merkel cell carcinoma (MCC).*
- Maintenance treatment of patients with locally advanced or metastatic urothelial carcinoma (UC) that has not progressed with first-line platinum-containing chemotherapy.
- Patients with locally advanced or metastatic UC who:
 - Have disease progression during or following platinum-containing chemotherapy.
 - Have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.
- First-line treatment, in combination with axitinib, of patients with advanced renal cell carcinoma (RCC).

*This indication is approved under accelerated approval based on tumor response and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

Policy/Criteria

Provider must submit documentation (including such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.

It is the policy of health plans affiliated with Centene Corporation[®] that Bavencio is **medically necessary** when the following criteria are met:

I. Initial Approval Criteria

A. Merkel Cell Carcinoma (must meet all):

1. Diagnosis of metastatic MCC;
2. Prescribed by or in consultation with an oncologist;
3. Age \geq 12 years;
4. Request meets one of the following (a or b):*
 - a. Dose does not exceed 800 mg every two weeks;
 - b. Dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (*prescriber must submit supporting evidence*).

*Prescribed regimen must be FDA-approved or recommended by NCCN.

Approval duration: 6 months

B. Urothelial Carcinoma (must meet all):

1. Diagnosis of recurrent, advanced or metastatic UC;
2. Prescribed by or in consultation with an oncologist;
3. Age \geq 18 years;
4. Member has received platinum-based chemotherapy (e.g., cisplatin, carboplatin);
5. Prescribed as a single agent;
6. Request meets one of the following (a or b):*
 - a. Dose does not exceed 800 mg every two weeks;
 - b. Dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (*prescriber must submit supporting evidence*).

**Prescribed regimen must be FDA-approved or recommended by NCCN.*

Approval duration: 6 months

C. Renal Cell Carcinoma (must meet all):

1. Diagnosis of advanced RCC (e.g., relapse, stage IV disease);
2. Prescribed by or in consultation with an oncologist;
3. Age \geq 18 years;
4. Prescribed as first-line therapy in combination with Inlyta[®];
**Prior authorization may be required for Inlyta*
5. Request meets one of the following (a or b):*
 - a. Dose does not exceed 800 mg every two weeks;
 - b. Dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (*prescriber must submit supporting evidence*).

**Prescribed regimen must be FDA-approved or recommended by NCCN.*

Approval duration: 6 months

D. Other NCCN Recommended Uses (off-label) (must meet all):

1. Diagnosis of one of the following (a or b):
 - a. Gestational trophoblastic neoplasia;
 - b. Endometrial carcinoma;
2. Prescribed or in consultation with an oncologist;
3. Age \geq 18 years;
4. For gestational trophoblastic neoplasia: Prescribed as a single agent following failure of \geq 2 systemic chemotherapeutic agents (*see Appendix B*);
5. For endometrial carcinoma, both of the following (a and b):
 - a. Prescribed as a single agent second-line treatment (*see Appendix B*);
 - b. Disease is recurrent or metastatic for microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) tumors;
6. Request meets one of the following (a or b):*
 - a. Dose does not exceed 800 mg every two weeks;
 - b. Dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (*prescriber must submit supporting evidence*).

**Prescribed regimen must be FDA-approved or recommended by NCCN.*

Approval duration: 6 months

CLINICAL POLICY
Avelumab

E. Other diagnoses/indications

1. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace and CP.PMN.53 for Medicaid.

II. Continued Therapy

A. All Indications in Section I (must meet all):

1. Currently receiving medication via Centene benefit, or documentation supports that member is currently receiving Bavencio for a covered indication and has received this medication for at least 30 days;
2. Member is responding positively to therapy;
3. If request is for a dose increase, request meets one of the following (a or b):*
 - a. New dose does not exceed 800 mg every two weeks;
 - b. New dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (*prescriber must submit supporting evidence*).

**Prescribed regimen must be FDA-approved or recommended by NCCN.*

Approval duration: 12 months

B. Other diagnoses/indications (must meet 1 or 2):

1. Currently receiving medication via Centene benefit and documentation supports positive response to therapy.
Approval duration: Duration of request or 6 months (whichever is less); or
2. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace and CP.PMN.53 for Medicaid.

III. Diagnoses/Indications for which coverage is NOT authorized:

- A.** Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policies – CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace and CP.PMN.53 for Medicaid or evidence of coverage documents.

IV. Appendices/General Information

Appendix A: Abbreviation/Acronym Key

dMMR: deficient mismatch repair	NCCN: National Comprehensive Cancer Network
FDA: Food and Drug Administration	RCC: renal cell carcinoma
MCC: Merkel cell carcinoma	UC: urothelial carcinoma
MSI-H: microsatellite instability-high	

Appendix B: Therapeutic Alternatives

This table provides a listing of preferred alternative therapy recommended in the approval criteria. The drugs listed here may not be a formulary agent and may require prior authorization.

Drug Name	Dosing Regimen	Dose Limit/ Maximum Dose
Gestational Trophoblastic Neoplasia		
Examples of systemic chemotherapeutic agents: bleomycin, carboplatin, cyclophosphamide, dactinomycin, etoposide, gemcitabine, ifosfamide, mesna, methotrexate, paclitaxel, vincristine.	Varies	Varies
Endometrial carcinoma		
Examples of systemic chemotherapeutic agents: carboplatin/paclitaxel, cisplatin/doxorubicin, carboplatin/paclitaxel/bevacizumab, doxorubicin, topotecan, temsirolimus, ifosfamide	Varies	Varies

Therapeutic alternatives are listed as Brand name[®] (generic) when the drug is available by brand name only and generic (Brand name[®]) when the drug is available by both brand and generic.

Appendix C: Contraindications/Boxed Warnings

None reported

V. Dosage and Administration

Indication	Dosing Regimen	Maximum Dose
MCC, UC	800 mg IV infusion every 2 weeks until disease progression or unacceptable toxicity	800 mg every 2 weeks
RCC	800 mg IV infusion every 2 weeks in combination with axitinib	800 mg every 2 weeks

VI. Product Availability

Single-dose vials: 200 mg/10 mL (20 mg/mL)

VII. References

1. Bavencio Prescribing Information. Rockland, MA: EMD Serono, Inc.; November 2020. Available at: <https://www.bavencio.com/>. Accessed November 11, 2021.
2. National Comprehensive Cancer Network Drugs and Biologics Compendium. Available at: http://www.nccn.org/professionals/drug_compendium. Accessed November 11, 2021.
3. National Comprehensive Cancer Network. Merkel Cell Carcinoma Version 1.2021. Available at www.nccn.org. Accessed November 11, 2021.
4. National Comprehensive Cancer Network. Bladder Cancer Version 5.2021. Available at: www.nccn.org. Accessed November 11, 2021.
5. National Comprehensive Cancer Network. Endometrial Carcinoma Version 1.2022. Available at www.nccn.org. Accessed November 6, 2020.

CLINICAL POLICY
Avelumab

Coding Implications

Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to-date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.

HCPCS Codes	Description
J9023	Injection, avelumab, 10 mg

Reviews, Revisions, and Approvals	Date	P&T Approval Date
1Q18 annual review: Specialist added to MCC and UC. Age added to MCC. Dose added to UC; “Locally advanced or metastatic” removed given inclusion of criteria requiring progression following platinum-based chemotherapy NCCN bladder cancer use delineating “as a single agent” removed. References reviewed and updated.	11.20.17	02.18
1Q 2019 annual review; HIM Medical-Benefit line of business added; no significant changes from previously approved corporate policy; age added to UC; reference to bladder cancer as off-label use is removed from the UC criteria set as it and other cancers are included under UC histology; references reviewed and updated.	11.13.18	02.19
RT4: criteria added for new FDA-approved indication for RCC; references reviewed and updated.	05.29.19	
1Q 2020 annual review: added HIM line of business; removed HIM-Medical Benefit; examples added per NCCN for advanced RCC, limited to first-line therapy per PI and NCCN; references reviewed and updated.	11.19.19	02.20
Added Commercial line of business; RT4: criteria updated for newly FDA-approved indication for maintenance treatment of UC for those who have not progressed after platinum therapy.	09.15.20	
1Q 2021 annual review: for UC, recurrent disease added per NCCN, and platinum-based chemotherapy history added per label and NCCN; gestational trophoblastic neoplasia off-label use added per NCCN; references to HIM.PHAR.21 revised to HIM.PA.154; references reviewed and updated.	11.06.20	02.21
1Q 2022 annual review: added criterion that Bavencio be used as single-agent therapy for urothelial carcinoma per NCCN; added endometrial carcinoma indication per NCCN; references reviewed and updated.	11.11.21	02.22

CLINICAL POLICY

Avelumab

Important Reminder

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members

CLINICAL POLICY**Avelumab**

and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

Note:

For Medicaid members, when state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.

©2017 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene[®] and Centene Corporation[®] are registered trademarks exclusively owned by Centene Corporation.